Please use this identifier to cite or link to this item: https://biore.bio.bg.ac.rs/handle/123456789/5132
DC FieldValueLanguage
dc.contributor.authorPerić, Stojanen_US
dc.contributor.authorZlatar, Jelenaen_US
dc.contributor.authorNikolić, Lukaen_US
dc.contributor.authorIvanović, Vukanen_US
dc.contributor.authorPešović, Jovanen_US
dc.contributor.authorPetrovic Đorđevic, Ivanaen_US
dc.contributor.authorSrećković, Svetlanaen_US
dc.contributor.authorSavić-Pavićević, Dušankaen_US
dc.contributor.authorMeola, Giovannien_US
dc.contributor.authorRakočević-Stojanović, Vidosavaen_US
dc.date.accessioned2022-11-21T10:07:03Z-
dc.date.available2022-11-21T10:07:03Z-
dc.date.issued2022-07-18-
dc.identifier.citationPeric S, Zlatar J, Nikolic L, Ivanovic V, Pesovic J, Petrovic Djordjevic I, Sreckovic S, Savic- Pavicevic D, Meola G, Rakocevic-Stojanovic V. Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2. Front Neurol. 2022; 13:932883.en_US
dc.identifier.issn1664-2295-
dc.identifier.urihttps://biore.bio.bg.ac.rs/handle/123456789/5132-
dc.description.abstractIntroduction: Myotonic dystrophy type 2 (DM2) is a rare autosomal dominant multisystemic disease with highly variable clinical presentation. Several case reports and one cohort study suggested a significant association between DM2 and autoimmune diseases (AIDs). Aim: The aim of this study is to analyze the frequency and type of AIDs in patients with DM2 from the Serbian DM registry. Patients and Methods: A total of 131 patients with DM2 from 108 families were included, [62.6% women, mean age at DM2 onset 40.4 (with standard deviation 13) years, age at entering the registry 52 (12.8) years, and age at analysis 58.4 (12.8) years]. Data were obtained from Akhenaten, the Serbian registry for DM, and through the hospital electronic data system. Results: Upon entering the registry, 35 (26.7%) of the 131 patients with DM2 had AIDs including Hashimoto thyroiditis (18.1%), rheumatoid arthritis, diabetes mellitus type 1, systemic lupus, Sjogren's disease, localized scleroderma, psoriasis, celiac disease, Graves's disease, neuromyelitis optica, myasthenia gravis, and Guillain-Barre syndrome. At the time of data analysis, one additional patient developed new AIDs, so eventually, 36 (28.8%) of 125 DM2 survivors had AIDs. Antinuclear antibodies (ANAs) were found in 14 (10.7%) of 63 tested patients, including 12 without defined corresponding AID (all in low titers, 1:40 to 1:160). Antineutrophil cytoplasmic antibodies (ANCAs) were negative in all 50 tested cases. The percentage of women was significantly higher among patients with AIDs (82.9% vs. 55.2%, p <0.01). Conclusion: AIDs were present in as high as 30% of the patients with DM2. Thus, screening for AIDs in DM2 seems reasonable. Presence of AIDs and/or ANAs may lead to under-diagnosis of DM2.en_US
dc.language.isoenen_US
dc.publisherFrontiers Media S.A.en_US
dc.relation.ispartofFrontiers in Neurologyen_US
dc.titleAutoimmune Diseases in Patients With Myotonic Dystrophy Type 2en_US
dc.typeArticleen_US
dc.identifier.doi10.3389/fneur.2022.932883-
dc.identifier.urlhttps://www.frontiersin.org/articles/10.3389/fneur.2022.932883/full-
dc.description.rankM22en_US
dc.description.impact4,086en_US
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.fulltextNo Fulltext-
crisitem.author.deptChair of Biochemistry and Molecular Biology-
crisitem.author.deptChair of Biochemistry and Molecular Biology-
crisitem.author.orcid0000-0002-8304-2067-
crisitem.author.orcid0000-0002-2079-4077-
crisitem.author.parentorgInstitute of Physiology and Biochemistry "Ivan Djaja"-
crisitem.author.parentorgInstitute of Physiology and Biochemistry "Ivan Djaja"-
Appears in Collections:Journal Article
Show simple item record

SCOPUSTM   
Citations

11
checked on Nov 10, 2026

Page view(s)

67
checked on Nov 10, 2026

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.